Lipocine (LPCN) Total Non-Current Liabilities (2012 - 2024)
Lipocine's (LPCN) quarterly Total Non-Current Liabilities came in at $1.6 million in Q3 2024, down 29.61% YoY from $2.2 million in Q4 2023, and down 6.22% on a QoQ basis from $1.7 million in Q2 2024.
Lipocine (LPCN) Total Non-Current Liabilities (2012 - 2024) Analysis & Trends
Lipocine (LPCN) has 8 years of Total Non-Current Liabilities data on file, last reported at $1.6 million in Q3 2024.
- Quarterly Total Non-Current Liabilities fell 29.61% year-over-year to $1.6 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.6 million (down 29.61% YoY) and the FY2023 annual result came in at $2.6 million, up 55.8% from the prior year.
- Total Non-Current Liabilities eased to $1.6 million in Q3 2024, from $1.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $7.3 million in Q1 2021 to a low of -$37.2 million in Q1 2022.
- A 5-year average of -$9.4 million and a median of $1.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 222.14% — and 2022, when it slumped 606.16%.
- Tracing LPCN's Total Non-Current Liabilities over 5 years: stood at -$10.0 million in 2020, then surged by 161.11% to $6.1 million in 2021, then tumbled by 72.56% to $1.7 million in 2022, then soared by 55.8% to $2.6 million in 2023, then sank by 39.66% to $1.6 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $1.6 million (Q3 2024), $1.7 million (Q2 2024), and $1.4 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 2.61 Mn |
| Sep 30, 2023 | 2.24 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.93 Mn |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | -32.21 Mn |
| Jun 30, 2022 | -35.45 Mn |
| Mar 31, 2022 | -37.18 Mn |
| Dec 31, 2021 | 6.12 Mn |
| Sep 30, 2021 | -31.29 Mn |
| Jun 30, 2021 | -35.54 Mn |
| Mar 31, 2021 | 7.35 Mn |
| Dec 31, 2020 | -10.01 Mn |
| Sep 30, 2020 | -9.37 Mn |
| Jun 30, 2020 | -9.29 Mn |
| Mar 31, 2020 | -6.01 Mn |
| Dec 31, 2019 | -4.48 Mn |